INmune Bio Non Operating Income Net Other Over Time

INMB Stock  USD 7.53  0.12  1.62%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out INmune Bio Performance and INmune Bio Correlation.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
  
The current year's Non Operating Income Net Other is expected to grow to about (1 M).
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.09)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.63)
Return On Assets
(0.45)
Return On Equity
(0.99)
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Non Operating Income Net Other Analysis

Compare INmune Bio and related stocks such as Tff Pharmaceuticals, Anebulo Pharmaceuticals, and Abcam PLC Non Operating Income Net Other Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareRoic
Inventory TurnoverNet Income Per Share
Days Of Inventory On HandPayables Turnover
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityRoe
Tangible Asset ValueEv To Operating Cash Flow
Pe RatioReturn On Tangible Assets
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D ADividend Yield
Earnings YieldShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
CUE165.3 K165.3 K165.3 K165.3 K165.3 K165.3 K165.3 K165.3 K165.3 K64.1 K64.1 K64.1 K64.1 K64.1 K57.7 K91.8 K
ANIX36 K16.9 K(475.2 K)(3.2 M)17.6 K12.5 K1.6 M46 K71.4 K33.9 K104 K104 K104 K104 K119.6 K125.6 K
AVXL(702.3 K)(534.5 K)(534.5 K)(8.4 M)(4.9 M)870.6 K2.2 M1.7 M2.7 M4.7 M4.3 M2.4 M2.4 M2.4 M2.8 M2.9 M
SAVA901 K901 K451 K106 K47 K57 K107 K38 K105 K328 K112 K483 K483 K483 K434.7 K456.4 K
BIVI0.00.00.00.00.00.00.00.00.03.3 M3.3 M3.3 M3.3 M3.3 M3.8 MM
CGTX(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(35 K)(31.5 K)(33.1 K)
TCRX415 K415 K415 K415 K415 K415 K415 K415 K415 K415 K415 K415 K415 K415 K373.5 K332 K

INmune Bio and related stocks such as Tff Pharmaceuticals, Anebulo Pharmaceuticals, and Abcam PLC Non Operating Income Net Other description

My Equities

My Current Equities and Potential Positions

INmune Bio
INMB
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 7.53
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out INmune Bio Performance and INmune Bio Correlation.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
INmune Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of INmune Bio technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of INmune Bio trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...